Profile data is unavailable for this security.
About the company
Zenith Drugs Ltd is an India-based pharmaceutical company. The Company is mainly engaged in the business of manufacturing and trading of medicine. The Company offers a range of formulations in various forms, such as ORS powder, liquid oral, ointments, creams, gels and liquid externals, capsules, tablets. Its liquid oral products include Aceclofenac & Paracetamol Suspension; Albendazole Oral Suspension BP 25 mg/ml; Ambroxol Hydrochloride & Levocetirizine Dihydrochloride Syrup; Bromhexine Hydrochloride Syrup 4mg/5ml; Cetirizine Dihydrochloride and AmbroxolHydrochloride Syrup; Cetirizine Dihydrochloride and AmbroxolHydrochloride Syrup; Chlorphenamine, Ammonium Chloride and Sodium Citrate Syrup; Chlorpheniramine Maleate Oral Solution USP 2 mg / 5 ml, and others. Its ointment products include Cetrimide Cream BP 0.5% w/w, Chloroxylenol Cream 0.8% w/w, Ciprofloxacin Cream 0.5% w/w, Ciprofloxacin with Fluocinolone & Clotrimazole Cream and others.
- Revenue in INR (TTM)1.44bn
- Net income in INR37.77m
- Incorporated2000
- Employees182.00
- LocationZenith Drugs LtdK No 72/5 Village Muradpura DepalpurINDORE 453001IndiaIND
- Websitehttps://www.zenithdrugs.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Accretion Pharmaceuticals Ltd | 573.76m | 67.94m | 761.45m | 121.00 | 11.21 | 4.98 | 10.06 | 1.33 | 6.11 | 6.11 | 51.62 | 13.75 | -- | -- | -- | 4,741,835.00 | -- | -- | -- | -- | 30.44 | -- | 11.84 | -- | 0.557 | 8.30 | 0.4799 | -- | 70.43 | -- | 75.30 | -- | -- | -- |
| Zenith Drugs Ltd | 1.44bn | 37.77m | 793.99m | 182.00 | 21.03 | 1.11 | 8.76 | 0.552 | 2.20 | 2.20 | 83.88 | 41.82 | 0.9315 | 2.80 | 2.33 | 7,903,775.00 | 2.45 | -- | 4.48 | -- | 33.80 | -- | 2.63 | -- | 0.9561 | 1.54 | 0.4198 | -- | 1.29 | -- | -24.92 | -- | -- | -- |
| Curis Lifesciences Ltd | 502.59m | 62.06m | 840.78m | -- | 13.55 | 5.09 | 12.22 | 1.67 | 7.68 | 7.68 | 62.17 | 20.43 | -- | -- | -- | -- | -- | -- | -- | -- | 36.59 | -- | 12.35 | -- | 0.7449 | 27.07 | 0.486 | -- | 41.27 | -- | 23.51 | -- | -- | -- |
| Vaishali Pharma Ltd | 1.17bn | -3.86m | 852.18m | -- | 24.40 | 1.54 | 492.87 | 0.7262 | 0.3258 | 0.3258 | 11.82 | 5.16 | 1.04 | 54.91 | 2.48 | -- | -0.3418 | 3.19 | -0.5293 | 6.67 | 11.29 | 15.64 | -0.3289 | 3.43 | 2.33 | -1.59 | 0.188 | -- | 14.77 | 10.51 | 13.70 | 90.26 | 42.08 | -- |
